CAY10415 is used to study blood glucose levels and rates of insulin-stimulated lipogenesis.
ChEBI: 5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]thiazolidine-2,4-dione is an aromatic ether.
msdc-0160 is a prototype mtot-modulating insulin sensitizer [1].msdc-0160 is a thiazolidinedione insulin sensitizer without the peroxisome proliferator–activated receptor-γ (ppar-γ)-dependent side effects. co-incubation of islets with msdc-0160 and igf-1 reduces the resistance of insulin-signaling pathway and preserves insulin content. msdc-0160 at 50μm alone also prevents the loss of insulin content significantly. besides that, treatment of msdc-0160 increases the phosphorylation of ampk and reduces mtor phosphorylation. moreover, msdc-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2. in addition, msdc-0160 exerts prevention of nuclear translocation with β-catenin localized on the cell membrane or cytoplasm in human β-cells [1].
MSDC 0160 (Mitoglitazone; 30 mg/kg; oral gavage; daily; for 7 days) improves locomotor behavior, increases survival of nigral dopaminergic neurons, boosts striatal dopamine levels, and reduces neuroinflammation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice[2].
| Animal Model: | Ten- to 12-week-old male C57BL/6J mice weighing 24 to 28 g[2] |
| Dosage: | 30 mg/kg |
| Administration: | Oral gavage; daily; for 7 days |
| Result: | Improved locomotor behavior, increased survival of nigral dopaminergic neurons, boosted striatal dopamine levels, and reduced neuroinflammation.
|
[1] rohatgi n, aly h, marshall c a, et al. novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets. plos one, 2013, 8(5): e62012.
